{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040946","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.735278+00:00","generated_at":"2026-06-11T16:56:16.854567+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Larimar Therapeutics Q2 net loss $8.4M; FDA clears 50 mg cohort and OLE trial for CTI-1601 in FA","bullets":["Net loss of $8.4M (-$0.19/share) vs $8.7M in Q2 2022; cash $104.2M, runway into Q4 2024.","FDA cleared initiation of 50 mg cohort in Phase 2 FA trial and Open-Label Extension after review of 25 mg data.","Top-line data from 25 mg cohort showed CTI-1601 was well-tolerated and increased frataxin levels from baseline.","New CMO appointed: Russell Clayton, DO, replaces retired Nancy Ruiz.","Expect top-line 50 mg data in 1H 2024; OLE interim data in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040946","json":"https://secwatch.observer/filing/0000950170-23-040946.json","markdown":"https://secwatch.observer/filing/0000950170-23-040946.md","text":"https://secwatch.observer/filing/0000950170-23-040946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023040946/0000950170-23-040946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023040946/lrmr-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T16:56:16.854567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13012d349acc0fb6ccab78e2b219ce1d6de2053d","claim":"Larimar Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $8.4 million, or $0.19 per share, EPS $0.19 per share.","evidence_excerpt":"The Company reported a net loss for the second quarter of 2023 of $8.4 million, or $0.19 per share, compared to a net loss of $8.7 million, or $0.47 per share, for the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023040946/0000950170-23-040946-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$8.4 million, or $0.19 per share"},{"label":"EPS","value":"$0.19 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}